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Abstract
Activin and TGFb share SMAD signaling and colon cancers can inactivate either pathway alone or simultaneously. The
differential effects of activin and TGFb signaling in colon cancer have not been previously dissected. A key downstream
target of TGFb signaling is the cdk2 inhibitor p21 (p21
cip1/waf1). Here, we evaluate activin-specific effects on p21 regulation
and resulting functions. We find that TGFb is a more potent inducer of growth suppression, while activin is a more potent
inducer of apoptosis. Further, growth suppression and apoptosis by both ligands are dependent on SMAD4. However,
activin downregulates p21 protein in a SMAD4-independent fashion in conjunction with increased ubiquitination and
proteasomal degradation to enhance migration, while TGFb upregulates p21 in a SMAD4-dependent fashion to affect
growth arrest. Activin-induced growth suppression and cell death are dependent on p21, while activin-induced migration is
counteracted by p21. Further, primary colon cancers show differential p21 expression consistent with their ACVR2/TGFBR2
receptor status. In summary, we report p21 as a differentially affected activin/TGFb target and mediator of ligand-specific
functions in colon cancer, which may be exploited for future risk stratification and therapeutic intervention.
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Introduction
Activin is a member of the TGFb superfamily that regulates cell
differentiation, proliferation, and apoptosis in many epithelial and
mesenchymal cells [1]. Similar to TGFb, activin utilizes two types
of surface receptors with intracellular SMAD2, 3 and 4 for signal
transduction. Activin receptor 1 (ACVR1B) and activin receptor 2
(ACVR2) are transmembrane proteins with extracellular ligand-
binding activity and intracellular serine/threonine kinase activity.
ACVR2B does not substitute for the functions and signaling of
ACVR2 [2].
In particular, ACVR2 was found mutated in the majority of
colorectal cancers with high frequency microsatellite instability
(MSI-H), primarily due to a frameshift in the A8 tract of exon 10
[3,4]. Restoration of activin signaling, its growth suppression,
growth arrest and its induction of migration occur when ACVR2 is
complemented [5]. We have previously demonstrated high
frequency of ACVR2 mutations in MSI-H colon cancer specimens
in conjunction with loss of ACVR2 protein expression [6] and
showed that ACVR2 loss is associated with larger colon tumors
and poor histologic grade [7]. Both ACVR2 and TGFBR2
mutations commonly occur simultaneously in MSI cancers [6],
and cell lines also can lose both TGFb and activin signaling [8].
Interestingly, both receptors are less commonly inactivated in
MSS colon cancers, which tend to have a worse prognosis than
MSI-H colon cancers [9], and both pathways may be targeted
independently. To date, little is known about the distinct
contribution of activin signaling to colon cancer development
and metastasis and specifically, how TGFb and activin signaling
effects differ despite identical intracellular SMAD signaling.
p21 (also known as p21
cip1/waf1) is a cyclin-dependent kinase
inhibitor controlling cell cycle arrest via cdk1 and 2 inhibition and
is a master regulator of multiple tumor suppressor pathways via
both p53-dependent and independent mechanisms [10]. It is a
known target gene of TGFb in colon cancer [11], and has been
associated with activin-induced growth arrest in plasmacytic and
breast cancer cells [12,13], but effects of activin on p21 in colon
cancer cells as well as downstream consequences have not been
assessed.
In this study, we explored the mechanisms of TGFb and activin
on p21 regulation and the ensuing functional effects thereof in
colon cancers. We found that despite identical intracellular SMAD
signaling, TGFb and activin regulate p21 via diverse mechanisms
that are functionally relevant in colon cancer leading to more
apoptosis or reduction in growth suppression dependent on the
activin/TGFb signaling status with p21 as a differentially
regulated target.
Results
In the Presence of SMAD4, TGFb is a more Potent Inducer
of Growth Suppression While Activin is a more Potent
Inducer of Apoptosis
To test and compare the effects of activin and TGFb on cell
growth, we used colon cancer cell lines with differing SMAD4
status as described elsewhere [22,23] in addition to SMAD4
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lite stable colon cancer cell line FET and ACVR2/TGFBR2 wild
type/SMAD4-null SW480 colon cancer cells were treated with
either activin or TGFb and cellular growth was assessed. As an
additional control, SMAD4 was knocked down via siRNA in FET
cells which were treated and analyzed accordingly. While both
activin and TGFb treatment led to significant growth suppression
in SMAD4 wild type FETs, the effect was more pronounced
following TGFb treatment. In contrast, neither ligand was growth
suppressive in the absence of SMAD4 in ACVR2/TGFBR2 wild
type/SMAD4-null SW480 colon cancer cells or following SMAD4
knockdown in SMAD4 wild type FET cells (Figure 1A).
We then compared apoptosis induction of either ligand in the
presence and absence of SMAD4 or p21. Activin induced
apoptosis to a greater extent than TGFb, and apoptosis only
occurred in the presence of SMAD4 (Figure 1B, C). SMAD4/
p21 dependence was confirmed by an alternative apoptosis assay
determining BrdU-labeling of intracellular DNA fragments.
Apoptosis was increased following activin and TGFb treatment
in SMAD4 positive FET cells, with activin inducing a greater
degree of apoptosis. No induction of apoptosis with either ligand
was observed in SMAD4-null SW480 cells or FET cells following
SMAD4 knockdown paralleling the TUNEL experiments
(Figure 1B, C). p21 knockdown in SMAD4 wild type FET cells
resulted in loss of apoptosis induction (Figure 1D).
In conclusion, this data suggests that although activin and
TGFb share intracellular SMAD signaling, each favors distinct
downstream physiologic effects at consistent doses. Additionally,
we show that both growth suppression and apoptosis induced by
either ligand are SMAD4-dependent.
Activin Regulates Nuclear p21 in a SMAD4-independent
Manner
One of the known growth suppressive target genes of TGFb is
p21, which is upregulated following TGFb treatment in FET
colon cancer cells [11]. The effect of activin on p21 in colon
cancer has not been assessed. To analyze the downstream effects
of SMAD4-dependent activin signaling, we determined p21
expression following activin treatment compared to TGFb
treatment. Contrary to the previously known TGFb effects on
p21, we found no increase in p21 transactivation and only a
modest increase in transcription following activin treatment in the
presence of SMAD4, while TGFb markedly induced both p21-
specific transactivation and transcription when SMAD4 was
present (Figure 2A). With regard to p21 protein expression, we
found that in contrast to TGFb, activin treatment decreased
nuclear and total p21 regardless of the presence of SMAD4, while
cytosolic p21 remained relatively constant (Figure 2B). To further
analyze the regulation of p21 protein by activin, we performed a
time course showing that after slight initial upregulation, p21
protein is downregulated by 24 hours following activin treatment
(Figure 2C, two adjacent right lanes).
To confirm that the ligand effects on p21 were directly
dependent on SMAD4, we knocked down SMAD4 in SMAD4
wild type FET colon cancers cells using siRNA. We found that
baseline p21 expression in FET cells decreased with SMAD4
knockdown (Figure 2D, lane 3), which substantiates the
importance of the SMAD4 pathway for the maintenance of high
p21 levels in this cell line [11]. Consistently, TGFb-induced
upregulation of p21 was abolished with loss of SMAD4
(Figure 2D, lane 7). As expected, the downregulation of p21 by
activin was not affected by the absence of SMAD4 (Figure 2D,
lane 5) which is consistent with our Western blot analysis of p21
levels in FET and SW480 cells (Figure 2B) showing downreg-
ulation of p21 in the SMAD4 positive and negative cell line. Thus,
SMAD4 signaling appears to be required for processes that are
dependent on high p21 expression, but dispensable for processes
associated with low or decreased p21 levels.
Activin-induced Growth Suppression is Dependent on
p21 Expression, and SMAD4/p21 Signaling can
Counteract Activin-induced SMAD4-independent
Migration
Subsequently, we sought to determine the functional role of p21
in activin-induced growth suppression and cell viability. We found
that loss of p21 via siRNA knockdown resulted in abolishment of
activin-induced growth suppression in SMAD4-wild type cells,
indicating that activin/SMAD4-induced growth suppression is
p21-dependent (Figure 3A). Further, loss of p21 not only led to
abrogation of activin-induced cell death, but also to an increase in
cell numbers suggesting a survival benefit with loss of p21
(Figure 3B). These observations underscore the importance of the
SMAD4/p21 axis in activin-mediated growth suppression and cell
death.
Accordingly, we tested the role of the p21 in activin-induced
migration by assessing cellular mobility in the presence and
absence of SMAD4. We found that activin enhanced migration
in SMAD4 positive and SMAD4 negative cells (Figure 3C),
which argues for a SMAD4 independent pathway regulating
migration. This data is supported by similar findings in TGFb
signaling for which a strong pro-migratory and SMAD4-
independent effect was shown [20,22]. As activin treatment was
associated with a decrease in p21 levels as well an increase in
migration, we expected that loss of p21 by knockdown would
enhance baseline migration as well as migration after activin
treatment in SMAD4 intact cells, if the remaining p21 was at
least partially involved in counteracting activin-induced migra-
tion. Consistent with this hypothesis, we show an increased basal
migration rate in SMAD4 expressing cells following p21
knockdown (Figure 3C) as well as overall more pronounced
migration upon activin treatment (Figure 3D).
We further found that basal cell migration was enhanced by
activin treatment in the absence of either p21 or SMAD4 in
SMAD4-positive FET cells, but that knockdown of p21 had no
additional effect on migration when SMAD4 was absent, as in
SW480 cells (Figure 3D). For TGFb, we found that cell
migration was enhanced regardless of the presence of p21
(Figure 2B, Figure S1D). This supports again that p21-
mediated effects following activin treatment are dependent on
SMAD4 and that p21 acts downstream of SMAD4 for its anti-
proliferative and anti-migratory effects (Figure 4). Further, this
suggests that, in the case of TGFb, some promigratory signals can
bypass SMAD4 as previously postulated [22] circumventing p21
and its inhibitory effects. In summary, we deduce that p21 may
counteract migration downstream of SMAD4 and that downreg-
ulation of p21 may be responsible for some of the pro-migratory
potential of activin signaling. Thus, differential regulation of p21
may be at the center of distinct functional effects of activin and
TGFb.
Activin Treatment Leads to Ubiquitination of p21 and
Inhibition of Proteasome Abolishes Activin-induced p21
Downregulation
To further dissect the mechanism of activin-mediated p21
protein decrease, we assessed p21 ubiquitination following activin
treatment and its dependence on the proteasome (Figure 5A, B).
For this, we compared p21 ubiquitination following activin and
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39381Figure 1. In the presence of SMAD4, TGFb is a more potent inducer of growth suppression and activin a more potent inducer of
apoptosis. A) After ACVR2/TGFBR2/SMAD4-wild type FET, FET cells following transient SMAD4 knockdown, and ACVR2/TGFBR2-wild type/SMAD4-null
SW480 cells were treated with vehicle (control), activin or TGFb for 24 hours, the metabolic activity via MTT-growth assay was assessed. Growth
suppression occurred only in the presence of SMAD4 following both activin and TGFb treatment (***p,0.001). Further, TGFb led to a significant
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39381increase in growth suppression compared to activin (***p,0.001). B) To determine the rate of apoptosis, a TUNEL assay was performed in SMAD4-
wild type FET, SMAD4-KD FET, and SMAD4-null SW480 cells treated with control vehicle (C), activin (A), or TGFb(T). Apoptosis was determined by
TUNEL-labeling of apoptotic bodies. C) Normalization [% apoptotic bodies/nuclei] revealed that activin- and TGFb-induced apoptosis occurred
predominantly in SMAD4-wild type FET and not in SMAD4-KD FET or SMAD4-null SW480 colon cancer cells. In the SMAD4 expressing cells, activin
induced apoptosis to a greater degree than TGFb (*p,0.05). D) BrdU-labeled intracellular DNA fragments, indicative of apoptosis, were determined
24 hour after activin or TGFb treatment of SMAD4-wild type FET colon cancer cells, FET cells with p21 KD, FET cells with SMAD4 KD and SMAD4-null
SW480 colon cancer cells. Increase in DNA fragmentation was noted after activin and TGFb treatment only in the SMAD4 wild type cells, with activin
inducing more fragmentation compared to TGFb. In the presence of SMAD4, p21KD lead to a basal increase in apoptosis, but activin treatment lead
to no induction of apoptosis. SMAD4 knockdown resulted in loss of apoptosis in FET cells akin to effects observed in the SMAD4-null SW480 cells
(*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0039381.g001
Figure 2. While TGFb increases p21 expression in the presence of SMAD4, activin decreases nuclear and total p21 independent of
SMAD4 status. A) SMAD4-wild type FET and SMAD4-null SW480 colon cancer cells were treated with vehicle (control), activin, or TGFb for 24 hours.
p21-specific transactivation was determined using a dual luciferase assay with pWWP-luc and pRL-TK (left panel) and mRNA expression levels of p21
were quantified by qPCR and normalized to L19 (right panel). While TGFb markedly induced both p21-specific transactivation and transcription in the
presence of SMAD4, no increase in p21 transactivation and only a modest increase in transcription following activin treatment in the presence of
SMAD4 were found (*p,0.05). B) SMAD4-wild type FET and SMAD4-null SW480 cells were treated with control vehicle (C), activin (A), TGFb(T), or a
combination of both ligands (A+T) for 24 hours prior to lysis for total protein, nuclear, and cytoplasmic preparation. Histone H3, a-tubulin, and
GAPDH were used as loading controls for the respective fractions. While TGFb markedly increased p21 levels in all three fractions in the SMAD4
positive cell line only, activin induced a decrease in nuclear and total p21 protein in SMAD4-positive and -negative cells (left panel). Densitometric
analysis of all blots revealed statistically significant changes in p21 levels (right panel) (ns = non-significant, *p,0.05, **p,0.01, ***p,0.001). C)
Initial upregulation of p21 protein is followed by downregulation by 24 h after activin treatment. SMAD4-wild type FET cells were treated with activin
or vehicle (control) and harvested at various time points for quantification of p21 protein expression. GAPDH was used as loading control and relative
expression was calculated via densitometry. D) While TGFb-induced upregulation of p21 was SMAD4 dependent, activin-induced downregulation of
p21 was still observed in the absence of SMAD4. SMAD4-wild type FET cells were treated with vehicle (CNT), activin or TGFb in the presence of either
scramble siRNA (SC) or SMAD4 siRNA (KD) and total p21 levels were determined. GAPDH was used as loading and C32 cell lysate as p21 positive
control.
doi:10.1371/journal.pone.0039381.g002
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p21 polyubiquitination (Figure 5A). Treatment with MG-132
proteasomal inhibitor abrogated activin-induced p21 protein
decrease, (Figure 5B), invoking ubiquitin-mediated proteasomal
degradation in activin-induced p21 downregulation. This is akin to
UV-induced p21 protein degradation [24], but distinct from basal
p21 proteasomal degradation [25], which does not employ
ubiquitination.
Nuclear p21 is Lost in a Subset of Primary Colon Cancers
with Intact ACVR2
We then assessed whether impaired activin/TGFb signaling
affected p21 localization in primary colon cancers. We determined
presence versus loss of nuclear p21 expression in 56 primary colon
cancer specimens of various genomic subtypes, and correlated this
data with the activin and TGFb receptor status (Table 1). We
Figure 3. p21 mediates activin-induced growth suppression and counteracts activin-induced SMAD4-independent migration in the
presence of SMAD4. A) FET cells were treated with either scramble (SC) or p21 specific siRNA (KD). Growth suppression was assessed by MTT-
metabolic assay following activin treatment. Activin induced cell growth inhibition in the presence of p21, but the effect was reversed in the absence
of p21 (*p,0.05). B) Total viability is decreased in SMAD4 wild type colon cancers following activin treatment in the presence of p21. FET cells were
treated with either scramble or p21 specific siRNA. Cell viability was assessed by trypan blue staining following activin treatment. Trypan blue positive
cells after activin treatment were decreased in presence of p21, but increased after p21 knockdown (***p,0.001). C) Activin (A) induces cell migration
in SMAD4-positive and SMAD4-negative cell lines. Cellular migration is induced in SMAD4-wild type FET cells and SMAD4-null SW480 cells following
activin treatment, but more pronounced induction of migration is seen in the absence of SMAD4. Loss of p21 leads to an increase in baseline
migration in SMAD4 expressing cells (*p,0.05, **p,0.01, ***p,0.001). D) p21 knockdown increases the overall pro-migratory effect of activin in FET
cells. Loss of p21 in the absence of SMAD4 does further increase migratory induction (*p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0039381.g003
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p21, and that this loss was associated with preservation of ACVR2
(Table 1 and Figure 6), suggesting decreased signaling through
the SMAD4/p21 axis, but intact activin SMAD4-independent
signaling. The opposite was the case for TGFBR2: Preservation of
TGFBR2 was associated with persistent nuclear p21 (Table 1).
This data is consistent with our in vitro findings of TGFb/SMAD4-
dependent upregulation of p21 and activin/non-SMAD4-depen-
dent downregulation of p21.
Discussion
In MSI-H colon cancers, both TGFb and activin signaling are
abrogated due to frameshift mutations in the type II receptor [26].
The loss of both of these signaling pathways may be beneficial and
additive for tumor growth [20,27], but the differential effect on
migration remains unclear. TGFb and activin utilize the same
intracellular SMAD proteins (SMAD2/3 and SMAD4) to transmit
their signal. Both ligand specific pathways are commonly
inactivated in MSI-H colon cancers, for which we previously
observed greater than 50% overlap between ACVR2 and TGFBR2
mutations [6]. Interestingly, they are less commonly inactivated in
MSS colon cancers, which tend to have a worse prognosis than
MSI-H colon cancers [9], and both pathways may be targeted
independently. Here we show that while activin and TGFb both
can induce growth suppression and apoptosis to varying degrees,
they also enhance migration, thus sharing in tumor suppressive as
well as cancer promoting properties. Fine-tuning of these opposing
effects as well as differential regulation of TGFb versus activin
signaling is likely an important process in carcinogenesis influenc-
ing the fate of cancer cells. This manuscript explores the
differential effects and regulation of activin and TGFb signaling
in colon cancer.
Here we show that in colon cancer cells, despite identical
downstream SMAD signaling, activin and TGFb have opposing
effects on the cdk2 inhibitor p21 resulting in distinct regulations of
each pathway. While TGFb has a strong up-regulatory effect on
p21, activin signaling leads to a slight decrease in p21 protein
levels. Interestingly, both ligands induce SMAD4-dependent p21-
mediated cell growth suppression and cell death, yet TGFb
appears to be a more potent inducer of growth suppression, while
activin on the other hand is a more potent inducer of apoptosis. As
previously described, both TGFb and activin enhance cell
migration [20,22]. Notably, we now show that activin’s pro-
migratory effect is regulated in a SMAD4-independent fashion
and describe for the first time a concomitant increase in p21
ubiquitination and proteasomal degradation. Hence, whereas
activin-induced growth suppression is dependent on p21, activin-
induced migration is accompanied by reduced p21 levels and
independent of SMAD4. While it is known that UV-induced p21
protein degradation is ubiquitinin-dependent [24], basal p21
degradation via the proteasome is not [25]. Recent data implicates
ERK2 in mediating nuclear to cytosolic shifting and ensuing
ubiquitinin-mediated degradation of p21 [28]. A variety of
ubiquitin ligases to include Ecto and Smurf-1 have been found
to target both SMAD-dependent and independent TGFb signal-
ing [29]. The specific ubiquitin ligase responsible for activin-
mediated p21 ubiquitination has not been determined to date.
Increase or decrease of p21 levels could drive a cell towards the
preferential activation of either the SMAD4-dependent or
independent signaling pathway and vice versa, thus modulating
the overall cellular response. Conclusively, p21 appears to be an
important player for the differential regulation of SMAD4-
dependent and independent pathways controlled by activin and
TGFb (Figure 4).
Figure 4. Schematic of proposed differential regulation and effects of activin and TGFb signaling on p21 in colon cancer cells. * is
indicative of total (cytoplasmatic + nuclear) p21.
doi:10.1371/journal.pone.0039381.g004
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SMAD signaling occur simultaneously and that the net effect is a
result of the relative context-dependent dominance of a given
ligand and/or pathway. Differential regulation of p21 may be an
important mechanism to control and fine-tune preferential
signaling dependent or independent of SMAD with potential
prognostic relevance. Loss of SMAD signaling has been associated
with increased migration and loss of growth suppression in colon
cancer [22], and we now show one possible mechanism in colon
cancer by which SMAD signaling may be bypassed via
preferential activin signaling, presenting an explanation for the
pro-migratory and pro-proliferative effects accompanying lost
SMAD signaling.
p21 plays a complex role in cancer. Tumor suppressive
properties of p21 have been described in the context of induction
of growth arrest, differentiation and senescence and studies in
different cancer types showed that p21 expression correlates with a
favorable diagnosis [10]. Consistent with the above finding, several
studies in colon cancer revealed an association between p21
downregulation and metastasis as well as poor survival [30,31,32]
[33], however, some reports point towards a dual role in several
cancers with increase of p21 correlating with poor outcome
[34,35].
Here, we report a substantial number of primary colon cancers
with loss of nuclear p21, which correlates with presence of ACVR2
and absence of TGFBR2. This is in line with our in vitro data
where we show downregulation of p21 in the context of enhanced
Figure 5. Activin-induced p21 downregulation is associated with ubiquitination and counteracted by proteasomal degradation. A)
ACVR2/TGFBR2/SMAD4-wild type FET cells were were pretreated for 30 minutes with proteasomal inhibitor MG-132 and then treated with vehicle
(control), activin, TGFb for 24 hours and ubiquitination of total p21 was assessed via immunoprecipitation of p21 and blotting with a ubiquitin-
specific antibody (upper panel) and reblotting of p21. Multiple bands indicative of polyubiquitination were seen only following activin treatment.B )
Activin-induced p21 downregulation is dependent on the proteasome. SMAD4-wild type FET cells were pretreated for 30 minutes with proteasomal
inhibitor MG-132 followed by treatment with vehicle (control) or activin for 24 hours and compared to cells treated accordingly without proteasomal
inhibition. p21 expression was assessed and showed inhibition of p21 downregulation following activin treatment in conjunction with proteasomal
inhibition.
doi:10.1371/journal.pone.0039381.g005
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consistent with the concept of an absent upregulation of p21 after
abrogation of the TGFb/SMAD4 axis, which can be explained by
knockdown of SMAD4, as in our experiments, but also by absence
of TGFBR2, as seen in the cancer samples. The functional
consequences we would expect from decreased p21 levels in
conjunction with preservation of ACVR2 and loss of TGFBR2
based on our data are enhanced migration via SMAD4-
independent signaling and loss of growth suppression through
the TGFb/SMAD4/p21 axis. Independent of the effect on growth
suppression, which alone has been found to be a weak prognostic
marker in many cancers [36], the ACVR2+/TGFBR2- receptor
status associated with loss of nuclear p21 points to a pro-metastatic
and thus more aggressive cancer phenotype. This is consistent with
previous findings showing that loss of p21 is associated with worse
outcome in various cancer types [10]. While other signaling
pathways may direct p21 localization, our data establish the basis
for further assessment of activin and TGFb receptor status in
association with p21 localization for prediction of outcome and
response to therapy in colon cancer.
In summary, our data show that TGFb is a more potent inducer
of growth suppression while activin is a more potent inducer of
apoptosis. Further, growth suppression and apoptosis by both
ligands are dependent on SMAD4 and p21. However, activin
downregulates nuclear and total p21 protein in a SMAD4-
independent fashion in conjunction with increased ubiquitination
and proteasomal degradation associated with enhanced migration.
TGFb on the other hand upregulates nuclear p21 in a SMAD4-
dependent fashion to affect growth arrest and may bypass p21 to
affect migration. Further, primary colon cancers show differential
p21 expression consistent with their ACVR2/TGFBR2 receptor
status. Conclusively, we report p21 as a differentially affected
activin/TGFb target and mediator of ligand-specific functions in
colon cancer, which might be exploited for future risk stratification
and therapeutic intervention.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of North Carolina
hospitals. All patients provided written informed consent for the
collection of samples as part of the under IRB approval conducted
North Carolina Colorectal Cancer Study (NCCCS) as referenced
below. The study was approved by the Northwestern University
Institutional Review Board (IRB#STU00020989). Written in-
formed consent was obtained from all participants.
Patient Samples
Colon tumors were prospectively collected under IRB approval
as part of the North Carolina Colorectal Cancer Study (NCCCS),
a population-based, case-control study comprising 503 patients
[14,15]. For this study, 15 patient samples with ample tumor and
normal tissue were randomly selected. For verification, we
collected an additional 41 consecutive colorectal cancer specimens
from Northwestern University under institutional IRB approval
(IRB#STU00020989) (Table S1). All tumors were formalin-fixed,
embedded in paraffin and cut into 5 mm sections.
Figure 6. Expression of p21 is lost in a subset of primary colon cancers correlating with the ACVR2/TGFBR2 receptor status. Fifty-six
colon cancers were stained for ACVR2, TGFBR2 and p21. Representative examples for p21 staining are shown: normal colon tissue with nuclear
staining (left panel), colon cancer sample with maintained nuclear p21 staining (middle panel), and colon cancer sample with loss of nuclear p21
staining (right panel).
doi:10.1371/journal.pone.0039381.g006
Table 1. Nuclear p21 expression in primary colon cancers
correlates with ACVR2 and TGFBR2 receptor expression.
A
p21 expression ACVR2+ (39) ACVR22 (17) p-value
nuclear (20) 7 13 0.0001
loss of nuclear (36) 32 4
B
p21 expression TGFBR2+ (29) TGFBR22 (27) p-value
nuclear (20) 17 3 0.0006
loss of nuclear (36) 12 24
A) ACVR2 expression correlates with loss of nuclear p21 in colorectal cancers:
x
2(1, N=56)=15.204, p=0.0001.
B) Loss of TGFBR2 expression correlates with loss of nuclear p21 in colorectal
cancers:
x
2(1, N=56)=11.755, p=0.0006.
doi:10.1371/journal.pone.0039381.t001
Activin and TGFb in Colon Cancer
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SW480 cells (ATCC, Manassas, VA) were maintained in
Iscove’s Modified Dulbecco’s and FET cells (generous gift from
Michael Brattain, University of Nebraska, Omaha, NE [16]) in
F12/Dulbecco’s Modified Eagles medium (both Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum and
penicillin G [100 U/ml]/streptomycin [100 mg/ml] (Invitrogen).
Cells were grown at 37uC in a humidified incubator with 5% CO2.
All cells were serum starved for 24 hours prior to experimentation
to approximate cell cycle synchronization. Cells were tested for
mycoplasma infection using the PCR Mycoplasma Detection Set
(Takara, Otsu, Japan) and authenticated by STR profiling using
the PowerPlex 1.2 System (Promega, Madison, WI).
Antibodies and Reagents
Activin A was reconstituted in PBS, TGFb1 in 4 mM HCl
according to manufacturer’s instruction (both R&D, Minneapolis,
MN) and used at final concentrations of 25 ng/ml and 10 ng/ml
as previously described [17,18,19,20]. MG-132 (Calchemie,
Darmstadt, Germany) was used for inhibition of the proteasome.
For immunohistochemical analyses, we used a goat polyclonal
antibody against ACVR2 (1:50) (ab10595, Abcam, Cambridge,
MA), as well as mouse monoclonal antibodies against TGFBR2
(1:50) (ab78419, Abcam) and p21 (1:150) (sc-817, Santa Cruz
Biotechnology, Santa Cruz, CA). For Western blotting, p21 (# sc-
469) (1:250) (Santa Cruz, Biotechnology), a-tubulin (# 3873), H3
histone (# 9715) (both Cell Signaling Technology, Danvers, MA),
and GAPDH (# sc-47724) (all 1:1000) antibodies (Santa Cruz,
Biotechnology) were utilized.
MTT-Growth Proliferation Assay
Cellular metabolic activity, indicative of the growth status of
cells following treatment with activin or TGFb was assayed using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (MP Biomedicals, Aurora, OH) as previously described
[20].
Cell Death/Apoptosis TUNEL Assay/Cellular DNA
Fragmentation ELISA
Cells were seeded in 6 well plates at a density of 10,000 cells per
well, serum starved for 24 hours and treated with ligand. 24 hours
after treatment, cells were lysed with trypsin and counted using a
hemacytometer as previously described [21]. Apoptosis was
determined using TUNEL staining with APOPTAG In Situ
Detection and DAPI counterstaining (Chemicon International/
Millipore, Temecula, CA), according to the manufacturer’s
instructions.
As an alternative assay of apoptosis, a photometric enzyme-
linked immunoabsorbent assay for the detection of BrdU-labeled
DNA fragments (Cellular DNA Fragmentation ELISA, Roche,
Indianapolis, IN) was used. Both FET and SW480 cells were
seeded in 6 well plates at a density of 10,000 cells per well. FET
cells were seeded with or without SMAD4 or p21 siRNA. After 24
hours serum starvation, cells were treated with ligand for 24 hours.
Apoptosis was determined via BrdU-labeling of intracellular DNA
fragments and quantified via anti-DNA antibody detection ELISA
according to the manufacturer’s guidelines.
p21 Luciferase Assay
The pWWP-luc plasmid (generous gift from B. Vogelstein,
Johns Hopkins University, Baltimore, MD), containing the
promoter of p21
cip1/waf1, was cotransfected with the Renilla-
expressing pRL-TK vector (Promega). Luciferase activity was
measured 24 hours after transfection by a dual luciferase reporter
system (Promega). Relative luciferase activity was normalized to
the Renilla luciferase activity as previously described [21].
Quantitative Expression of p21 mRNA
RNA was extracted using the AllPrep DNA/RNA Mini Kit
(Qiagen, Valencia, CA). RNA quality was assessed with the Agilent
Bio-Chip (RIN .9.5). One microgram of RNA of each sample was
reverse-transcribed using the Superscript III First-Strand Synthesis
SuperMix and Oligo(dT)20 primers by Invitrogen according to the
manufacturer’s instruction. Reverse transcription was followed by
RNase H digest (New England Biolabs, Ipswich, MA). Quantitative
PCR was carried out using specific primers for p21 (59-GACTCT-
CAGGGTCGAAAACG-39,5 9-GGAT-
TAGGGCTTCCTCTTGG-39). Each experiment was performed
as a standard curve experiment based on five serial dilutions (1:10),
utilizing the Fast SYBR Green PCR MasterMix (Applied Biosys-
tems, Foster City, CA). Each reaction was performed in triplicate
using a total reaction volume of 20 ml and a final primer
concentration of 100 nM. The experiments were performed and
analyzed on the 7900 HT Fast Real-Time PCR System (Applied
Biosystems) following the standard protocol and conditions for the
FastSYBRGreenMasterMix.Adissociationstagewasaddedtothe
run protocol to ensure specificity of the detected signal. For
normalization purposes expression levels of L19 were determined
accordinglyinthesameruntoexcludeeffectsofinter-runvariability
(59-ACCCCAATGAGACCAATGAAAT-39,5 9-CAGCC-
CATCTTTGATGAGCTT-39). The relative expression of p21
normalizedtoL19levelswascalculated foreachsampleand plotted
on a graph.
Total Lysis, Nuclear/Cytosolic Separation, and Western
Blotting
Cells were lysed using total lysis buffer RIPA (1% NP40, 0.1%
SDS, 1% DCA, 50 mM Tris HCl pH 7.2) with added protease
and phosphatase inhibitors as previously described [20,21].
Cytoplasmic and nuclear fractions were extracted with NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher
Scientific, Rockford, IL) according to the manufacturer’s instruc-
tion. Western blotting was performed using standard protocols
with 4–20% polyacrylamide gels, nitrocellulose membrane trans-
fers, overnight incubation with primary antibody at 4uC followed
by horseradish peroxidase-linked secondary antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) and detection by ECL
(Amersham, Little Chalfont, UK) [20,21], visualization, and
quantification of chemiluminescence with the LAS-3000 (Fujifil-
mUSA, Valhalla, NY).
siRNA and Transfection
Two specific siRNAs for each p21 and SMAD4 (Ambion,
Austin, TX and Santa Cruz Biotechnology) were transiently
delivered at a final concentration of 10 nM via electroporation
using the AMAXA Nucleofector (Lonza, Basel, Switzerland) in 12-
well plates at a density of 2610
6 according to the manufacturer’s
instructions. Transfection efficiency was confirmed using the
pmaxGFP
TM Control Vector (Lonza). Forty-eight hours post
transfection, colon cancer cells were lysed for subsequent RNA
and protein extraction.
Migration/Invasion Assay
Migration assays were performed as previously described [20].
Briefly, Corning Costar Transwell 12 well plates (8 mm pores,
Corning, NY) with fibronectin or matrigel (Sigma, St. Louis, MO)
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presence or absence of siRNA. Cells were then allowed to migrate
for 4 hours, stained, and images were captured using an Axiovert
2000 microscope with an AxioCAM HRC Camera (both Zeiss
Microimaging, Thornwood, NY). Images from 5 microscopic
fields at the center of each well were counted.
Immunohistochemistry for ACVR2, TGFBR2, p21
Expression and Localization
Slides containing primary colon cancer tissues were processed as
previously described [6] and stained for ACVR2, TGFBR2, and
p21 using the Catalyzed Signal Amplification System (CSA) by
DAKO (Carpinteria, CA). ACVR2 and TGFBR2 staining was
grouped into negative (no or weak signal) and positive (moderate
or strong signal) receptor status. The percentage of p21 positive
nuclei in each cancer samples was assessed. Tumors with more
than 50% of p21 positive nuclei were scored as nuclear positive
cancers. Slides were scored in a blinded fashion by two
investigators. Both investigators had to be in agreement for a
tumor to be called negative.
Immunoprecipitation, Ubiquitination Assay, and
Proteasomal Inhibition
Proteasomal inhibition was achieved by pre-treatment of cells
with 10 mM of MG-132 (Calchemie) for 30 minutes. 80 mg of total
protein lysate from various treatments were incubated with 1 mg
of p21 antibody (# sc-469, Santa Cruz Biotechnology) overnight
at 4uC. Protein G beads (Invitrogen, Carlsbad, CA) were added for
4 hours. After denaturation with sample buffer, Western blotting
was performed on 4–20% gradient gels (Biorad, Hercules, CA)
and nitrocellulose membranes after boiling for 15 minutes
incubated with antibodies against ubiquitin (1:1000) (# sc-8017)
antibody (Santa Cruz Biotechnology), p21 and IgG (# 111-035-
008; Jackson ImmunoResearch, West Grove, PA) or GAPDH (#
sc-47724; Santa Cruz Biotechnology) as respective controls.
Statistical Analysis
Differences between two respective groups were determined
using Student’s t-test. Probability values less than 0.05 were
considered to be significant. Data shown represents repeated
experiments on multiple biological replicates. For association of
p21 localization with receptor status, we performed Chi-Square
test calculations using the MedCalcH software (Version 11.6.1).
Supporting Information
Figure S1 p21 mediates TGFb-induced growth suppre-
sion and counteracts TGFb-induced SMAD4-indepen-
dent migration in the presence of SMAD4. A) FET cells
were treated with either scramble (SC) or p21 specific siRNA.
Growth suppresion was assessed by MTT-metabolic assay
following TGFb treatment. TGFb induced cell grwoth inhibition
in the presence of p21, but the effect was reversed in the absence of
p21. B) Total viability is decreased in SMAD4-wild type colon
cancer cells following TGFb treatment in the presence of p21.
FET cells were treated with either scramble (SC) or p21 specific
siRNA. Cell viability was assessed by trypan blue staining
following TGFb treatment. Trypan blue positiv cells after TGFb
treatment were decreased in presence of p21, but increased after
p21 knockdown. C) TGFb induced cell migration in SMAD4-
positiv and SMAD4-negativ cell lines. Cellular migration is
induced in SMAD4-wild type FET cells and SMAD4-null SW480
cells following TGFb treatment, but more pronounced induction
of migration is seen in the absence of SMAD4. D) p21 knockdown
increased TGFb-induced migration in FET cells. Loss of in the
absence of SMAD4 does not further increase migratory induction
(*p,0.05, **p,0.01, ***p,0.001).
(TIF)
Table S1 Characteristics of colon cancer patient cohort
randomly selected from North Carolina Colorectal
Cancer Study (NCCCS) (19, 20) (patients 1–15) and NW
cohort (patients 16–56) for p21 staining. Four patients from
the NW cohort did not have a stage information available (X).
(DOC)
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